1 unknown. 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Unknown 1 |
Follow Fangfang Zeng: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Soy Peptide, Conjugated Linoleic Acid, Overweight or Obese, Body Composition Experimental group, Control group - Overweight or Obesity | Not applicable | Unknown | Fangfang Zeng | 120 | 2021-05-14 | 2021-06-16 |
Non-alcoholic Fatty Liver Disease (1) · Obesity (1) · Overweight (1)
Control Groups (1) · Proteins (1) · Soybean Oil (1)
China (1)
PMID 17490954, PMID 25379623, PMID 27037767, PMID 27636835, PMID 30754681